Cytokinetics, Incorporated (CYTK) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, everyone. Thank you for standing by and welcome to the Cytokinetics Q1 2026 earnings conference call. This call is being recorded and all participants are in a listen-only mode. There will be no question and answer session after the company's prepared remarks. I would now like to turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Affairs. Please go ahead. Good afternoon and thanks for joining us on the call today. Robert Blum, President and Chief Executive Officer, will begin with an overview of the quarter and recent development. Andrew Callos, EVP and Chief Commercial Officer, will discuss the commercial launch of a mycorrhizal in the U.S. and readiness in Europe. Sadi Malik, EVP of R&D, will address the results from Acacia HCM. Stuart Kupfer, SVP and Chief Medical Officer, will provide updates related to our ongoing clinical development programs. Sun Lee, EVP and Chief Financial Officer, will provide a financial overview for the quarter. And finally, Robert will make closing remarks and review key milestones for the year ahead. As you can see on this slide, today's discussion will include forward-looking statements, which are subject to risks and uncertainties. Please refer to our SEC filings for a discussion of these factors. And now, I will turn the call over to Robert. Thank you, Diane. And thanks to all for joining us on the call today. The first quarter of 2026 has been a remarkable period for cytokinetics, and one that I believe reflects the emerging promise of what we have been building here for over 25 years. Most notably, we launched myCORZO, our first approved medicine for the treatment of adults with symptomatic OHCM in the United States. This is a milestone many years in the making, and that reflects our unwaveri...